2024-01-31-accounts

Charit%. registration number.. 11980Y5 Cornpani" registration nutntfT'. CL028473 AMMF - The Cholangiocarcinoma Charity IA CharitsblL lnc0rwra￿d Organisatioo Aj￿U41 Rerx)rt and Finan¢ial Stsi¢m¢nts r()r thL Yw l.'ndcd 31 Jknnuary. 2024 Edmund Carr LLP Chartered AccounLqnts &. StsiuLorv Audilor 146 Noi" London Road Chelmsford CM2 0.4￿"

AMMF- The Cholangiocarcinoma Charity Contents Retrerence and Administraiiie DeLqiIs TTusiees' Report In(l¢T￿n[1¢￿l F.xaTninels R¢￿)rt Statement of l.'inancial Actii'ilies iu Balance Sheei Siatemeni ol-C&4h Flo%¥s 12 N(ItLs 10 thL FinanLial StutL'menis

AMMF- The Cholangiocarcinoma Charity Reference and Administrative Details Chain￿an Mr Noel Co￿18an Trustees Mrs (jillian Corrigan Mr Ilarold C'orrigan Ir"1 om Nloremeni Senior MAnAgemtnt l Legdtrship Mrs I lelen Moremeni. C'LO Tea Registered Office FDierpri%e H(w Ilassing￿￿rn Road (ansied C-N124 IVW. "I hL Lh￿￿11￿. 15 inc(ryrdteil in F.n8land and WalLs. I11)8(15Tr5 Charit). ReELStrAtion P*umber C'ompan). Registration Number Cl.:()28473 Independent Examlner l.'dmund C'urr l.l.I' L'hartlrl￿ Aw)viihir)LS & st￿￿tE)ry Auditor 146 N¢i4- 1.i)nd(In Ri)Jd C'hL,Imsford C-M2 IIAW Page I

AMMF- The Cholngi(bcareinoma Charity Trustees, report for the Year Ended 31 January 2024 The trustees preseni their rewrt ￿1th the financial sthiements of the charity. for the N&)r ended 31 Januarv 2024. Th¢ Irustces halc ath)pied the proi isions ot'Accouniing and Reporting M. C hariiies.. Staiement ol- R¢LI)tntn¢Dd¢(I Pr￿ILliCe appliL4ble ty) LhJriiies Pre￿riNg theiT aLxvunts' in aLLiIriL￿L¢ with the Finuncial R¢pirting Siandard dppIiL<ibl¢ in th¢ IIK Jnd R¢puhliL vfiT¢l<lnLI (FR% 10?) leff¢Llii¢ l Jiinu and wiihoul intLrrupti<)n %inLL thL inLLpli()n ol. IhL ('[() ()n Ul Junc 2022. 'TIVITIE AMMF'S ￿ll￿fIl0￿ A impriiiiEI li)r thL ih()langi(urLinoma paliinl M ihL sharing of k"[￿111¢d8C acr055 thL hculthLarc and r¢sLJrLh iiimmuniti¢b 'ith the family vf aff￿1¢d p￿Trple a¢ro&s th¢ globe. A￿lMF.$ N'ISION A ￿.(￿rI￿ iihLrL pLx)plL Lan livc thcir livL￿ fTCC ofcholangiocarcinoma ICCAI as a lil￿threalcning di5case. AMMb' thi C'hi)langi(>cariiniima Charitv 15 the onl ¢harih' in th¢ IIK sol¢lN ddi¢alcd io ihvlongiiKar¢ini?m IbilL duLI LdnLLrl. AMNIF Mc)rks naiii)nall￿ ihn)ughi)ui thL Ilk. &% I¥LII as in F.uropL. and Ll)Ilabt)raiL% 8lc)hall}'. AMMF 15 wholly commiued naiionallv and inlernationallv to tacklin8 ihe deN"aslaling canccr, cholangi(Karrinoma IC-CAI on all fronts and. uliimat¢lv. ￿ help find a Cu￿. through.. 8upwn- Pri)vidin8 inforn?aiion to indii'iduals or 8ft)UPS 10 supwrt a paiLenL or IovLxI one along iheir journe EmpoMcrmtht- Emtxiw'crin8 palicnis and thcir ioi'cd oncs to adi"￿tC for themsel￿¢5. scek bctlcr are, ntw trealment opiions and serond opinion5 Acce&5- Advocating for patients io ensur¢ th• hake acc¢55 kn the latest treatsllent options and a minirnum 51andar(l of Trr¢ aN>ropTial¢ lo thern A warene%%- Rai.%ing aMarertess Lh(Tr1an¥ltsL￿elrtthMa tt) sup￿r[ ￿ller diagnosis, fair and equal acLe%s io ireatmenis, inLluding nei%" treaiment apprtsaches Rcsodrch- Encoura8in8 and supp(Lin8 coniinucd re￿h into cau￿& diagnosiics, and n¢￿ treatrncnt options lor ihosL i%"iih Lholangiocarcinoma PoliLV Working ￿)￿'ardS cnsuring hcalih carc p)licies reflcc( the needs of thosc M'ith holangi(wcinotna Page 2

AMMF- The Cholangioeareinom Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) Chiilangi(ILxfLin(Ima is und¢r-r¢pr¢s¢nd a[￿ und¢r-[Und￿ i￿rOsS #ll arw inLludin¥ PL)IiLv, 5ff¥'iLYS, and research. It is a p)orlJ undLrsts)od and under reS￿rched disL&SL iihich is increasing in inLidenLe not onlv in the LIK but Ihroughoui Ihe iiorld. Lack of aiiareness and ihe difliculties of achiei'ing clear and accuraie diagnosj5. Mean that mosi are ai an ath'anced stage and inoperable at ume of their diagnosis. Whilst surgery ￿MainS th¢ onlv tx)ientiall!' ¢urdti¥¢ trukneni. ther¢ is noii palliati￿¢ ¢hemotherapJ and immunoiherapTr, and a 8roi¥in8 numbcr ol-elinical trials in particular thosc ini'estigaiing lurther ￿rgeted therapie5 and immunoiherapies. I loiiei'er, a diagnosis of inoperable cholangi(urcinoma remains ini'ariablj. lutul, Jn(I thi.4 is u siiuJti()n ihat n()[ LhanB, Ikiih paliLnts and thLif Larer5, cliniLians, healthcare profL￿510nals. fLscarLhers. and ry)lici' makers. as i￿¢11 as act1￿clY Ltsllai)oratiog glolwlly. l)urins lh¢ J¢ar 2023, lh¢ ¥harity ¥oniinu¢d its odi'o¢ao' Ivork. ¢sp¢¢iall% in h¢lping thos¢ ii'iih Lh()lan8iocarLinoma ￿ na%'i8ate Iheir ii'av ￿ c￿lin￿e esseniial trea￿ents M'hem'er pTrssihlc. Ralslng Awaren¢s$ A￿l￿F.5 C'holAllQlOt9r¢inomg Dgta Project l.dLk iil-riihusl daiJ liir Lhi)lan8iiiLJrLiniimd IC'C'AI has lon8 bcc￿ $Cl￿ bi. AMMI-' as a mJj()r rea￿)n ￿hV thLYc 1% %[} liltlL ()I'ihi% LanLLr. %[} liltlL pr1j¥rL￿. R()bu%i dats urL i%¢￿lIa1 11) 4Jrii'L ryiliL)', t() LnLx)uru¥L LurL'h lunding, to SlimulaiL intL'rL%i, and su much mi)re. AMMI.".4 C'hi)lan¥ii)LJfLini)ma l)JrJ prt)jLXI. ()f l￿1)rni￿1￿5 imrrf)nanLL l() thL LhJril)' s wiirk u)wJrd4 impr()ILd dii'arLnL%% n(?1 ()nl}' (II'C-L'A iL%LII', bui IhL nurnbcr (?f unmil in this JrLJ, finall) uimplLILd during 21123. m¥ lindings ￿¢ had prei'iously noi aiiar¢ or. Kc). findings includc.. C-Q'A is no l()ngcr as rarc as prn'iou51!' lunsldcrn￿. il is a 8Th?￿"1n￿ unlargC￿d pr(iblcm. Mi)rn than haifof ¢hi)sc diagn05cd li ith C'C'A Nrcii"cd no canrcr S￿lf1¢ Ircaimcnt al all. "I"hcrL ha￿C b￿rt no improicmcnts in C'C-A suTh"ii'al ralcs in d¢cadcs. PL(Ipli fri?m lh¢ m1Tr31 diprii.cd barkgrovnd5 11"er¢ found ¢0 b¢ almos¢ 40%1¢s5 lik¢lv tsF SUrn'iv¢ after a C('A dI￿n￿￿1￿ 1(?mpJrtxl Lv thi IrdSt dLryii¢il. This data work has rcsultcd in thrcc PaF￿ published in scicnlific journal5.' Regional I'arialion in roules to diagnosis of ehoJangiocareinom¥ in England from 200￿2017 Foi. LhL lull p￿￿r in I4.1?rld Jiiumal É)IlJ&%tri)LmlL'ri)Ic?¥i. ￿￿..- hup%-./.'i%iiii.iijgnLI.uimll 0117- 93271fullil 29..'j2413824 htm C.htslgngiocxrtinom atross England: a natitsnxl Studi" of temporl thgnges in in¢idtnte, survlvgl And routes to dia21105is by re%ion nd so¢iot¢onomi¢ depriiAtion. For ihL lull papLr in.Illcp RLport5. scc.. Illi C'ohort Study to asst55 gtographical variation in cholangioc8rcinom8 tTCatmtnt in F.ngland FÉ)r thL full PJPL'r in W'IiTld JÉ)urnJl i)f ri￿￿l[()InlL*11n￿l anuil(?g!-. %L'L.- IILI 52114ilulli￿ 151ilJ2U77.h Pa8c 3

AMMF- The Cholngi(bcareinoma Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) Rethink Liver C.'ancer C.amp8igD 8nd Whitt Paper Backed bv ihL findin85 of AMMF-S CCA data projLYI, oc￿t￿r 2023-s Lii'er CancLr All"arL￿eSS Monih the launch ol-the charity's major-'Re(hink Liver Cancer campaign iiith social media coi'erage and a press release. The b￿￿￿paIgn lauDLh lh¢ pre￿5 rtl¢i1Se gaID￿j significanl ￿¢￿1￿ aU¢niivn, m()51 n()tablv in.. Mail Onlin¢ I Mail on Surtdti), The Times and The E.%press 'I'o coincide with the launch of the campaign. AMMI.. wepaTed a White Paper. ii'ith a fore￿ord from Professor Shuhid Khan. I[n[￿'r1uI C()Ilt'g¢ l.(Inth)n. (iuilinin¥ the fjndings i)f th¢ dala pN)jeLt and i¥ith spcLific asks f()r improi¥m¥nts w ￿, madL JLross ¢hL Ix)Jrd. A WLsiminsr rLLeption is planned lor Februar% ?0?4. iihcre AMNif i¥ill share the details ofihL I￿,hIlL Paper and ils asks i¥iih Ihc)sL within 8ovemmeni and thL NI [% iiho c¥n ihan8c wlicv. and hai'e the ahiliiN' ti) brin8 atx)ut imptt)iements tor those Jiagnosed iviih cbo1angi￿rcIDMa. For (hL R¢lthink Lii'er Lan¢¢r Campai8n 4¢tsils and th¢ whi￿ P?￿r. s¢¢.. htips:l/ammf.org.uLlr¢think-lii'¢r- LanLLrl A￿l￿F'S Ilybrld European CholAtt2io¢sr¢inonx# C'onferttt¢e 2023 AKIK11,' i%Ji dvli¥hi¢J li) i¥¢liiim¢ ti%() ini¢mJlic>nall% rL'niii%n¥￿ ￿￿KIaliSL￿ Ji th¢ for¢fTr)ni ol. th¢ C'LA ￿Orld. l)ri)li'%siir Jiihn IlridblLi%aiLr IIIKI an¢J l)rtTrfL￿￿)f I.{)rL￿/￿ Riinatysa IILLl% l. as uTr-LhaiT% (Il-IhL, 21123 Li)nlLrLncL'. 'I'hLJ L.xrLrtIN hc)stLd a laiu11￿ i)l-m()rL than 411 iniLYnaii(INI speak¢r5 Jnd manJ¥¢d 51)me Lhallen¥iji)¥ V & A 'I'hL. full pn)8rammL and all ¢(￿r¢￿'niC pr¢x'nthiions from th¢ ihre¢ ¢Jays rLYord¢.d and rLmain alailabl¢￿ li) VILW viu AMMI.. WLbsitL'. %L'L.: hiips'.Ilammr.or8.uklammf￿nrlrLncL￿2￿23l Global C'holangiocarcinoma Allinct 'I'hL (iliibJl C'hiilangi()LarLiniima AlliJnLL ICrC'AI liils ¢sthbli5h¢d al ANIMI.- s illiLmalii>nal ii(Irk%h(?p hLld in l.()ndi)n in 21118. 'I'hL' Jim i)f IhL' AllitinLL' is l(> pr[￿ idL' d uniiLbd I'i)iLL' Ihr(iUbth inLL'maii()ndl Li)Ildh?rdii(?n. L() prÉ)N idL a plJll()rrn on Mhiih t() build links L¥LhangL knoMlcdgc in ordcr l() raisL thL gl(Ihal III- LC-A. l(1 irnpr(IkL thL Lxluiati(In ol-IK)th hLalthiarc prL)IL55iunals and PalILn￿ (o addrLSS Lurrlnl LhallLngL5. inLI thi li('A'.% inL¢Pli()n in ?{118. AMNII. i()niinuiyl Iii thi niiL-(i)r-pr4)fii PiLrth¢r in this ￿k￿L￿r¢. AMMTr .% C'l.'l) I ILILn Nli)rLmLn( js J Ll)-Lhdir i)n ihc inLernaiioNI %ieL'rin8 LY>mmiiiLC. l)uring 2023 ih¢ s¢cr¢¢ariat orth¢ tiC'A Sal w.ith th¢ h¢althwe communicalions agcnty AXON, who manag th¢ iK'sp(Ik¥ i%"¥b%iti Jrtd 3VLial mlxlia 4L¢¢iTrun15. and alw thr orgiinisaiivn vf th¢ ￿n￿41 Wi?rld Chi)langiiiLdfLini)md Day. c)n 15 Febr￿r¥ 2023. Public Benefit In li?rming thi rhariiy s Obj￿Ilv¢S and planning thc adiviIi¢5. th¢ tyus*¢5 hili¢ con5id¢r¢d th¢ Charity Ci)mmissii)n's guidance in res￿LI ofpublLL ￿ner11. Page 4

AMMF- The Cholngi(bcareinoma Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) .'HIEVEMENTS AND PERFoR￿lAN AMMF'S Research A￿ardS AMMI.. remains cvmmillcd to 5UPIK>rting research into cholangiocarcirK>ma. In )023. based on the adice of AMKIF'.4 SLientiliL Adi is()Th Bu<ird rfikndrds ii'rre VIT¢r￿ i￿(1 aLL¢pied b), the r(?110￿1￿¥ iu supp(irt their rLSLarLh inio LholangioLarLinoma: University of Glasgow IProfe550r Chiar* Braconi & Dr Jen Mortonl- AMMF ref.. 20231218 'IdLDiifying thLrup¢uiiL i)ptKirtuniiiL% f()r Elili￿. c￿LeT￿ bi. ini'i%iigLiiiing diL fiTS1 instalmcnl of ihc aivard of£35.IXK) agrccd i(1 fund thc i%(IrK- iil-l)riil¥%%)r C'armini ManiYn¥ in. 'I'hL r(Trlc of'i-I111%1.-11111%2 and l)l.'l)l.- in th¢ l}-mphuli¢ dIS￿n11ndIT0n i)f th¢ intrahiwJtlL ihC?lan8i￿dr￿in(1ma. id¢niifiLdlii)n (Trc(kTrM.nstru￿ si8nalling" Lnlversit) of Nottingham - A￿l￿F Ref: 2022QIS j?2.111111 paid iin 117.11.2112.1 r¢'pr¢s<nling Ih<' lull amount of th¢ award mad¢ ts) Professors 5hcela J%iwJrJm4Ln. AnnJ liralxTrMksa. Kci'in Gasion, to fund th¢ir iiDrk.'C'vmbinatiiTrn th¢rapics for Lhc)Idn811)LJfLini)ma" AMMF'S External Activities The LharitN 1% rec4)8ni/Ed liide1￿. naiic)nalli' and iniemaiii)nalli'. am()n8%1 boih ihe general public and ￿1th1n mediLal LifLles. flir lis iiL)rk in the field i)fchi)lan8lOLarLinoma. and is frequenLI!' inVi￿d kn i￿.i)Me part ol. siudTr groups and adNisor! knards. tor cxamplc. thc i4OTking group for Li%cr Transplanution for C'holangiocarcinomA and the ¢¥¢culii"e committee ol-Cholangiocarcinotna-UK. AMMF is alm) a member ofthe Europtran NeLi%i)rk lor the Studi 4)ICholangii)carcinoma IENS-CCAI. an association ol-research groups from across Eurott and knond. aeLii"clK" iiorking on basic. Iranslational. and clinical research into cholangiocarcinorna. and AMMF s CEO 15 chair of the LN5Q'CA Patient Adi'ocacv C'(irnmiti¢¢. Page 5

AMMF- The Cholngi(bcareinoma Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) AMMF L(Intinu¢s t(} 4Llii'¢ rn¢mlxr i)fcan¢¢r52, th¢ allianre of rar¢ 1¢55 unLer organisaiions in thL UK. AMMF-S CEO. HLlcn Morement i12s aprrf)inicd a board dIreC￿r of Cancer)2 in 2014. and ha5 continued in Ihat role since ihen. She also aaed as interim Co-chair during the Near Iii'ith fello C'ancer52 board member. Rebecca Porth. C'LU of "I"he Urolog!. l.oundaiionl 14'hilsi a neil" chair of rrustees w."as s()u¥ht. Thry)ugh tn¢mbuship (Il-C' naiiortal LdnLLr initiative and AN(MF s tnlstLL￿ see this as prni iding an imp)fiani opw)rtunilV ￿ iwork mo closelN' with this incrcasin8lN' intlucniial or8anisaiion. and in idenLifying prioriL>' ehallen8es and oprrf)rtuniiies lor all those in the rare and less eommon cancers communitv. A￿l￿F Involvtmetht BSG Gu&dtllthes for the DIRnosk ttd Mxn%emttht of Chol#hgloerolnoth# C'ornmis5iollLd IhL BSG 114rili5h SoLiLli tsl-Gtisif(ILntLrolob)% I dnd publishLd in Gl.11- in SLPILmher 2023. these are the most comprehensi%'e guidelines tor the dia8nosis and mana8emeni OI'LCA since 2012. IILaJm SMC. and N IC'F- new thtrapv apprai￿19 l)urin¥ 211?.I AMMI.. ini iliEI. bi)Ih ptitiLmi ftscing orgattisaiii)n iirjd u Pilticni ad¥'i)LiiiL'. (() submii u'riliL'n and iirdl.%lalLYnLni% in suptmirt i)fnL w ihirJp% apprai￿15. b% Ix)Ih thi %MC- {%ix)Ilish NILdiLinL% C'i)n5()rliun)l and NIC'I,. INdiii)nal In%titUlL. fcTrr C'drL' Jnd l..xLI.IILllLI'I. WL dfL' l%￿Liall￿ grdiL'lul ￿ iiii) AMNqI.' %uppi)rtL'r% ￿11￿ lir41-hJnd LNritriLniL ()I'C'C-A. AndTLa ShLJrd()i%'n Jnd Andi C'IJ). iih() JIM) ts)iik pJrt in ihL NIC'I.. apprni5J15 and. ailin¥ ab PatiLni 5pukL k.hall'ufall thi)sL i¥iih C-LA. New ¢heropi¢s l()r iholan8i(Kar¥inoma aENYo%'ed during 2023: PL'mbri)liiumJb- a 2nd line trvdimeni for those with hi8h micr(>salliie instabiliL>' l)r mi%rnaL.h repair dLliLicnLV C'C-A l)uTralumab i%ith Cjcmcilabinc and C-isplatin- an imtnunothcrdpy gii'cn M'ith a combinalion of hLm. thc Spanish Ambassador 10 ihc Hol!. Scc in Rome. Page 6

AMMF- The Cholngi(bcareinoma Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) Proi'iding information for ihose who need it AMMF'S C EO aiicnded monthli i'irtual NHS LancLrehariTh briLfin8 mectin8S throughout 2023. These regular rneeiings, which began during ihe pandemic. are proi ing infonllatiie. proi"iding dethi15 of neil. deNelopment5 in NI IS processes and wlicie5 in a timel) rnanner. AMMI." s Kledical and Clinical Adi'iwTS are c￿ll￿cl¢d on a re¥ul(w basi5 fi)r h¢lp and Jdi'iLe un h()w t￿￿1 t() h￿dI¥ the mvr¢ diifiLuli P￿le￿L qu¢ri¢s the LhaTilv r¢ctiw¢s, and l(>r up io date inlormation on LliniLal irials. AMMF"5 w'ebsiie conlinued to ￿ updatrd Tegularly. and prO￿ldeS information on all as￿ of Lh{)1￿1￿¥1{)u￿1￿{￿Mu. inLluding Ir¢uttn¥niy ', IhLrL is a LcimprL'h¥nsikL list ol'thl ¢lini¥al trials ihai aTL aiJiiablL r¢¢tuiling in ihL UK. 14hiLh is pro%ing a waluablL resourcL 10 ML￿IcS and P4llitnis. 1¥ii74'.#mmf.or8.uk 'I'he charitv's active sTrcial media plaifonns kcpt sup￿rterS up kn date Mith inforniaiion of importance and le￿a￿Ll ¢(> Ih¢m ihrc)ughoul thi v¢tsr. ANIMF'S Fa￿.1￿￿}k pag¢ rM)14 has wme 6.¢M)O f()Ilowers, and the lolloii'ing on X lfrorm¢rly T￿l¢l￿rI. Insts8ram LinK¢dln wntinu¢s to gro￿. AMMI,. niiii ha5 thrcL privaiL. mLmk'ronl%'. suprrffft groups on l.aLLh(K)k.. C'hDlJn81()LarLini)Ina %uprrt)rt- I IK and l.'ur()pg.' liir Pati¢ni% and (-aTLVi. r()r PatienL% ()nli'. and r()r ih(i.%e ber¢ai'ed. 'I'he%e hJi'L IKx'ii L¥lrLmelv wLII '¢¢iK¢xI h> a broi¥ing numb¢r ol. uYs- lh¢ main lorijm. li)r Paii¢nis and LJr¢J%. hJs oi'lr 1.200 uscrs. 'I'h¢s¢ grÉ)ups Jrt, pr[)￿ ing an ini aluabl¢ r¥wur¢¢ lor paii¢nis io shar¢ inltsm)aiion. ltsr ¢hem its hclp and ¥uprM)rt L'aLh i?IhL'r. ThL rLNuirLmLnt lft)m individual Paii¢nts r.amilw mcmbcr5 for $￿Irl¢ infi)mialii)n rLguTding %pLLiuli5l Liin%uliani% and IrLatmLnis ¢()r)tlnU¢% ts) inLrLUSL. With ihL li idLr il14a￿nLss 1)l-th¢ LhaTilI'. inLrLa%ing inLidLnLL and gr()win8 rL'Lcigniiic)n i)fLhi)Idn8Il)LarLi￿)rnJ. it 1% anilLiP￿IlL￿l thi% drL'J 4)fMc)Tk' i¥ill Li)ntinuL ui bir()11. A5 we look 10 2024 . The Reihink ljiver ('Y4netr C'impai%n We51min5¢er Rereplion 'I'hL R¥ihink l.ii'Lr L'anL¥r LJmpiLign is É?n8()ing and 14.ill iM)niinu¥ iniii 211?4. l%[￿￿101[1 during l.¢hruJry's C'hi)ltinbljl)LdfLini)rnJ Al¥arLnL'￿3 Mc)nih iihL'n li-¥ iiill k. hc)Idin8 d fLKI'Plii)n in WL'%tmin%tLY. in thL' I Ii)u%i' ()f C'iirnm()n% I'LrraLL jlj(?n R(x)rn. lknis ￿ent w'ill k. ￿)5[(.￿ bi. l-.Ili(ii C-i)Iburn Ml> C-hair ()1'ihc AI>IXi (In C'anLLr. At that Ll'Lni. will 5haTL ihL dLtai15 ofAMMI." s WhiiL PapLr it5 ask5 14ith Lan LhJnge ￿)IllY and make a dilT¢renL¢ for ih05¢ diagno5¢d li iih Lholangi(Karrinoma. Centres of (CA Exptrtlse 'hL i)utLI)mLS C)I'thL (CA dala pft)jLLI and ihL ￿h11(all0n 4)I'ihL nLiI 14%CJ CiuidLlinL% f£)r thL I)iJ8n()%i% and Manag¢m¢n¢ of C-Q'A haie gii¢n ANIMI.- th¢ ammunilion to begin iiork" t()iiard5 Q-¢ntr¢s of C-C-A l..11)ert15e. l.'ir%l %l¢ps hJii' k'ln GLk¢n. %L iiirking grvup tsfMTrm¢ vf th¢ t(PP ¢XlKffl)" in CCA has bccn 5¢¢ UP. lind li"¢ c￿￿'¢t thL pri)jLLt li) gain mc?menium during 2024. AMMF'S Hybrid EuropeAn Cholangiocartinoma Conference 'I'hi' 21124 11)nli'r¢mi¢ li ill tJki' plJii 118- 111 MJN- iiiih Jn iniLmalii)nal farul¢N. And Fingllv AMMF has grow'n s(eadili' OVCT the )'cars and. Miih the conlinucd hclp ofio&al fundraisers and suprM)rter5. stM)nsor and adi i50r5, ￿e li ill continue our ￿'ork and rttnain fully cofftmittryj to I￿Orking towards a far better futu￿ for dll thos¢ diagnus¢d iliih ihvlangi(KwLinvm Page 7

AMMF- The Cholngi(bcareinoma Charity Tru5tees' report for the Year Ended 31 January 2024 (continued) At the heart of e￿eEVth1rtS do is the Lhoiangiocarcfftoma FFaiient at)d their families. and each and eiery da>, all of us at AMMF sirilc ioi%ards ihai improicd luiure lor all ihose dia8nosed ￿1th ihis mosi challenging of LunL¢rs. AMXIF li ill L(Intinu¢ ils ￿￿Tk uniil gi)al 15 re4￿h￿. FINANCIAL RE%'IEIV Financial review and reserves polity The ¢hariiv has Loniinued io sirengthen its fithancial p)silion durin8 ihe lear. 'I'he charitv ensures thal sU￿1clen1 reserves are reLqined in aTh appropriate forni w fund its curreni obli8ations. Where S￿LI1)l r￿¢￿1rLh PTI)j¢cts haiv the IJ¢sigpui¢ SU￿lL1¥￿L unre51rlL￿d T¢seri'es 10 ctsvcr th¢ Lxw¢t¢d fuiurc granis pa%'ablc oi'LY (h¢ i¢mi ot'ihc n¥￿tCh p￿JL1. STRUC'TI',RE, GOVERryANC"E AND MAP4AGEMENT Coverning document 'I'h¢ Chariiv is controlled by lis goi'emin8 th)¢um¢ni. a deed of ¢nJSL and ion51i(ui¢s an unin¢orp)rai¢d ¢hari(y. 18 November 2024 AppTIl%,￿ hv OTd¢r ¢)fih¢ Iwrd oftrusiee5 vn ............................. and si8ned its bchaifby= Page 8

AMMF- The Cholangiocarcinoma Charity Independeni Examiner's Report to the trustees ofAMMF - The Cholangiocartinoma Charity I report to the charity tTUStees rn). examination of the accounts of the charl￿. for the jear ended 31 January 2024 I￿h)Lh ar¢ s¢t out on P￿¢5 10 t(1 21. Responsibilities and basis of report As the Lh￿￿ll¥.s trustees i'(iu lire re5ry1115ible for the prepardlion of the accounts in accordance with the TequireTnenl% i)I' Ihe Charitie4 Aci ?01 I i-the ALt'I. I repon in res￿¢( of m> examination of the chariry s accounts wried OUL under seetion 145 of the Act and in carr)'ing out mi. examinaiion I hai'e lolloiled all ihe applicable Direeiions 8ii'en bs, Ihe L"hariiJ L'ommission undLr scclion 14515Xbl ol-lhc Aa. Independent exAminer'5 StAtemenl Sin¢¢ th¢ ¢harity s gross in¢ome ¢x¢¢¢Q¢d £250.0￿ l'our ¢xamin¢r MU￿ ￿ a m¢M￿r ol. a LN)d>' lisi¢d in LLtion 145 1)i-IIiL ALt. l Lonlimi thai l am qualilied io uThdcrtakc ihc eNaminaiion becausc l am a memhcr ol'ihe As50LiUtion ()I'C'hurtLfLxi L'LlrtifiLxI ACLOUnthn￿ which is onL' ol-lhe lisied Wies. I hail ii)mplLied m) cxaminution. l ￿)ntIM ihai n(} M￿{rial mii¢im hil%L LX)mc to m)" kntlLniion in Li)nneLlii)n 'iih lh¢ 4xJrninaii(>n giving me ¢ous¢ Ic> k.111￿¢ thai in an! moi¢rial ￿￿p¢¥I'. aCLiiuniing reLX)rds wcrc noi k¢o in rcsw orth¢ charii}' &$ wuircd bv scclion 130 of thc Aa,. or the aLLC)unLs do not aLcord iyiih ihose recorth.. or IhL' aLLI)unL% Ihi nc)i th)mpl%" w.ith ihL appliLJhlL rLyuifL'mLnL% uinLLrninky thL. fi)mi dnd LxillLLni i)r LL(Funi% £)ut in thL' C hJriiiL% IALLI)uni% Jnd FiLTX)rtsl FiL¥ulaiions 2(M121 i>ihL'r ihJn an> rLquifL'mL'nl Ihdi IhL aLL()unls 811'L u -IruL and liir i'lLlV i%'hiLh is n()i a mJitLr L()n%idLfLMI as part lif un indLpLndLnl examination. I hawe no i￿nC¢m5 and have ¢ome a¢r0￿ M) oiher m¥¢i¢ts in ¢onn¢¢iion iNith the ¢¥aminaiion io i¥hi¢h alteniion should hL, in this rep(Trrt in ordLY to ￿t￿le a PrO￿r un&irstsndin8 ofthe UCLX)ullLS io he reaLhLd MDtt8U ndrd fvliirrL'II I.'C'LA 146 NLM Li)ndon Road ChLlm51oTd C'N12 UAW 19 November 2024 Page 9

AMMF- The Cholangiocarcinoma Charity Statement of Fillancial Actii'ities for the Year Ended 31 January 2024 (Including Income and Expenditure Account and Other ComprehensiNe Income) Total 2024 Total 2023 Unnstrirted Restrided N•te Ineome Endtswmettts from: D(In<ilii)n% and ILgJLiL OthLr trading aLllI'iiies IniLsimLni InL￿ML 676.193 12.470 11.854 228.236 IA)4.429 12.470 1.854 1.030.491 7.760 1.397 'I'otal inLX)me 700.517 228.236 9211.753 1.039.648 Expenditure on: Riii%ill8 lund 6.271 6.271 871.925 4.115 69(1.-16(1 269.-109 'I'(Ilal L¥TK'ndilure 6111.887 2(Tr9.3(Jg 878.l¥b 71KI.481 Net inLomLIILNpLndiiur¢l .1 run%lir% bLI%VLLn lunds. 91.630 131.9?31 41.0731 50,557 339.1fy7 NL% rn(Il'LmLnl in lund4 5Y.7U7 ISl.1501 50.557 3341.167 Re¢on¢ili*tion of fund$ X76.124 89.746 965.870 626.7113 .1 c)lal lun(L% LarriL.d l(In%2rd 17 15.R31 Xll.5Y h5.8711 All (If thL Lharily's actiNilies deri￿¢ from e0lliinuin8 opcfdlion$ during the aixbi'e ti¥Y) period5. Pa2e 10

AMMF- The Cholangiocarcinoma Charity (Registration number: CE028473) Balance Shttt as 4131 January 2024 2024 21123 Note Fixed a55ets Tiin¥ihl¢ <1%4¢1S 10 4,219 6.615 c.urrent Y455et5 s1oLk5 Debtors C￿L￿h al bank and in hanil 6.6.15 46231 12 13 40.211 1.194.938 .01 8.643 C'reditors: Amounts falling due within one yesr 14 159.3A81 Net current *55ets Y59.25i Net ASSets .016.477 65.8711 unds ofthe charit).: Restricted income funds 17 8(1.596 89.746 Unrestricted iacomt funds 935.X31 %76.124 Toial fund$ 17 l.Illh.427 Y05.8711 'rhc finanLial statcmcnis on pagcs 10 ￿ 21 11.crc approi'cd b). thc lnJslc￿. and authori%cd f<)r i55uc on 18 NoYern.¥e.r 2024 and si8nLd on ihLiT ￿.h￿11.b).: Nlr SiiL,I C'iirri¥ ChaiMan Pa2e 11

AMMF- The Cholangiocarcinoma Charity Statement of Cash Flows for the Year Ellded 31 January 2024 2024 21123 Note Cash tIow5 frorn operaling 8etivitit5 Nei Mo￿£m¢Al irt rw￿ per SOFA 5U.557 339.167 Adjustmenls DepreLiaiion Ini'esimL'nt income 948 41.254 338.718 Vorking tApit*l adjustments DLxrLa%LilinLrn'asL'I in 411)ck.% In¢riasL in d¢biors InLrca￿l(dLLre￿8C) in Credi￿r5 751 12641 128.11671 167.115x1 12 14 123.-14? Net C&sh Ilthi%'s from operdlin8 aciiviij¢s 159.-1?7 241.-7?y Cfish flows from Invtstln2 gttlvities IntLrL%l rLLLiiJhlL and.4iniilar inix)mL l>urLhasL ol'tangible liycd asseis 1.854 1.397 17.5fy3 10 LtL%h IloiY% Ir()m ini'L81in8 IlCtii'iliL$ 11.6Yg 171.02 237.163 C'&%h and c&sh cquivalLnL% Ilt I l.Lbruary 71.114h 7.13.811.1 (￿h and cash cqui%'alcnts 31 January .142.072 971.114fi All ()f the c&4h Ilow's are derived fft)m eoniinuin8 operdiions durin8 the alxTri'e periods. Pa2e 12

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 l Accounting policie5 Statement of tomplixnce The aLLounis Ilinaniial siaiLmLntsi haiL ￿en prLV1rL￿d in aLYord&nLe %i'ith ihc sthiemeni ol- RCL￿mMendLd Practice.. Acci)un(ing and RLwrting bi. Charities preparing their accounts in accordance I￿1th ihe l.inancial RLtx)rting qtsnLlJrd appliLiihle in th¢ [ Ik RLpuhliL C)r Ireland IFRS 1021 i%%uLd ()n 10 Jul% 2a14 and Ilie I",inaniial RiP)rtin¥ Si￿￿tsrd appliLahlL in th¢ l1nilL￿ Kin¥th)m Rt'publi¢ ()I' IrLland IbR% I(121 ihe ChariiiLS ALt 2011 and UK GLnLrnll% ALLLI)Iisd PractlLL as li app]iL￿ Irom l Janllat? 2019. 'I'he accounts Ilinancial sta￿Ments) hai'e bttn wepared to giie a'wue and fairf i'ie%i' and have departed froni ihe L'huriiie% IALLI)unt5' Re￿)rI$l Kegulalic)ris 21M18 (MI!. i() Ihe e¥ieni re4uir¢d iii pr()%'ide u'lrue and IuiT VIraLiiLe elleliive fnim l April 2(Kb5 MhiLh has 5inLY ken ii'iihdraiim. BASIS of preparation AMMI.. I'h< C'hiilJn¥iiKarninoma C'harii). m¢rf$ th¢. dclittilion ol'a public t￿Melli cntitj undLr FR% 10? A.%%Lts nd lidhiliiiL% afL' initiallv reLI)bini%Ld ai hist()rieal eosi or iransaLli()n %'aluL unle&s 4)LhLf¥¥i%L' %LI(Ld in lh¢ rLILiant aLL4)untin8 poIiL? riotes. Golng eonetrn 'I'hL Iru%tLxs L(In%idLr tha¢ ihLYc n() malLrial uncLYtainliLs alx)ul thL &haritN's abilit￿ l() Liiniinul a4 a g(iing Li)niLrn nor an}. %ignili¢dni ar¢as ot'un¢¢ruini%" thai all¢Lt th¢ carry.ing Kalu¢ 4)f h¢ld b). th¢ ihariiy. In¢orne and tndowrnenls All inLiimL 1% rLLl)gnlsL￿ (InLL thc charilj has cniiilcmcni ￿ thc in￿)rnL. il 15 probable thai thc inc<)mc M'ill bc rLiciicJ and IhL amouni ol-thc incomc rcceiiablc ian bc mcasurcd rcliabl). leguL'le¥ l)(Inalion5 are r¢¥ogni5LYi i1.hen th¢ ¢harii!. h&$ been noiificd in writing of th¢ amouni and 5dtl¢m¢nt dale. In IhL' L'IL'ni thdt d dc>ndtL(In is.subjL'LI 1(1 L()ndi(L(In.s thai rLyuirL' d IL'L'I iifrKrfc)miJnLL' b% ihL' Lhdrii> k.fi)rL ih¢ Lharilv Is Lntitlcd to ihc lunds. Ihc income is dL1LrrL￿ and noi rcc08nlsL￿ unLil LiihLY LhoSL Cl)ndilions arL lullv mct. or the lullilmint of those condiiion5 is i%"holli i%"ithin the conlrol of the chaTlly and il is probablc thai ihe5¢ condition5 ￿.111 ￿ fulfill¢d in Te￿1￿8 period. Inveslmentlncome Diiidends are reco8nised once the diiidend h&$ tren declared and nOLiri￿10n has been reeeiN'ed ofthe dividend duL. Page 13

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 Expendlturt All L'xp¢nditure 1% r￿1)g￿l%¢￿ theT¢ 1% a legal {)[ Lonsltuttii"e i)bl]￿lI1)n li) thai expendilure, il i% prÉ)Tryahle settlLmLnt is reqUirL￿d and the amollni Can ￿ mLYsurcd reliabl!.. All c4)sis are allocated to ihL appliLable LKPLndiillrL' hLading thai a88fL8￿C similar costs io thai c￿e80Th. WherL' Losts cannoi bc dircLili attributed io particular headin85 the>. hal'e been allocated on a basis consisieni ii'ith the use of resources. i1.ith central stsff Lost5 alloLaied on the basis ol- time St￿￿L and depreciaiion charge5 allocafrd on the portion of ihe asscl-s use. Othcr 5UPtK)rt L05ts ure ' income. the mana8ement of investhients and those incurred in irading aLtii'ilies thai raise funds. CliJRliiible tteilvliles Lh<iriliiblL L.XKKllLliiurL u)mprisc4 ihosc ¢O%L% incurycd bi. the chariD' in ihe dclii'cry, of iLq aciii'iticq and %cTh'iccs li)r IL% bL'n¥li¢iJrii%. It inilud¢s LY)th ¢osis iha¢ bL' all(KaiLd dircL¢li W) su¥h ￿111"111¢$ and th<)sL ci)%ts c¥l' an indi￿[ naiure n¢¥¢ssatv ￿ suppN)n them. Governanee ¢osi$ 'I'hL%L iniludl ihL Liis1% utlTihulablL li) thL Lhuril). S LiimplianLx' %%ith Liill51ituli()Thul and Sthiui()ry rL4UITLmLnL%. inLluding (iudii. siraicgiL mana¥Lm¢ni and truslLxs mL'tin¥s rcimburs¢d Lxrrtnscs. Tangible nxed 55ets Indi￿1￿U￿1 IIxL'd LcTrsiin8 Éll.IIU i)r miirL arL' iniiialli" rm)rdLxI al o)SL l¥ss on). %ubsL4uinl J¢LumulaLLd dLprLLiJiiiin and %ub.%L4UL'nl dLLumulaiL￿ imp1iinllL￿t l()S5es. Deprecixtlon gnd amortisation l)LprLLialii)n 1% idlxi iin i￿¥1￿1¢ fiK¢d assds so as ¢0 iiTii¢ off the Cost or ialutyiion. less an>" ¢siimat¥d rL'iidiial idluL'. I)%'LY thLif L￿r￿L(l,d USL.ful LKM>nt)mLL lif¢ ￿ fi)Ili)14-%.' Asset cla55 Computer cquipmcnt Depreci*tlon meihod and rate 331J/ stock tolk is i'alLILQ at the lowcr ofcosl and Lslimatcd selling priec less Costs complell and scll. after duc rc8ard li)r ob501¢te and slow rnoving 5kKks. C051 15 d¢termincd using the lirsl-in. first￿ul IF IFOI. Trgde debtors I'r¢id¢ d¢bti)rs Jr¢ ￿￿￿nts due ftt)m ¢USlomers for m¢r¢hartdise sold or s¢rnir¢s p¢rfom¢d in lh¢ (Irdin(Yy Li)urse i)Ibusiness. Trade debtor5 are recognised iniliallv at the tran5artion price. Th• sub5equeritl)" rneasur¢d at atnort15ed c05t using th¢ ¢ff¢¢tii'¢ inl¢T¢bl rn¢thiNI. 1¢55 prtTri"iSi(In for itnpaiTm¢rtl. A pri?i'j5iiTrn f(IT th¢ irnpaimi¢nL (If iT¢id¢ debtor8 1% e%tabli%hed iihen there is i)bjeciiie ￿ idence the chariLN Mill noi be able (O LolleLt all ami)unts due according 10 Ihe original iernis ol'the receii ables. Page 14

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 Cash equlw9le￿ts C&%h Jnd L&%h L4uiidlLnL% c()mpTi4¢ Lash on hand an¢J Ljll de￿_ll and É)th¢r %h()rt-l¢rm highly liquid invLStmenis that arL' readilv convertible io a amount ot- Lash and are subjeci tt) an insignifiLani risk of LhangL in ￿alLIl. Tr￿de eredilors TradL' LrLdits)rs arL obligali()n% to pas. for gix)ds or.4ervitt4 that hale been acquired in the ()rdinaTV Cl)urse of hu%inL%% fri)rn %uppli¢v. AiLu)unts puNabl¢ iir¢ LI￿51r1￿1 Lurrcni liuhiliiiL% if the Lhurit> di)Ls niii hai'l an unLondilii)nJl righi. ai ihL Lnd ol. the rL'¢X)nin8 PLYi(x]. to delLf seiilLmLml i)( the erL￿ditQ)r lor ai leasi ii¥cli'e months aller Ihe reFQrting dale. If ihere is an unconditional righi 10 defer seulemeni (or ai leasi iii'eli'e months after the reFK>rting date. tho are presented as nor￿urrent liabiliLLes. I'rade LrLLlili)r% ure N'Logni%etl ioilially ai the irnnsaciion price and subwuenili measured ai amortised cost using (h¢ illiilll'¢ ini¢risi mLihod. Fund strueturt I InrL%triLtLd inLiimL lund% aTe gcncral fund% thal are aiailablc for use ai thc trus1cc￿% di%rclii)n in furthLfdnLe RL.%lriLILd inLomL lunsJ¥ are th(x%e donated li)r use in a particular area or for s￿li11l PUTrrf)se, thL u%e (IfwhiLh is rLsiri¢¢¥d t() ¢hut or purrrt)S¢. Flnanclal Instruments Clfi.islJl('uilTrn Financial as%LL% and linancial liabililies arc r¢¢o8niscd iithen the charil}' iwmc5 a parti io the ci)niraLlual pr(Ivision% ()I'th¥ instrumLnt. l.'inJnLial liJhilitlL'% dnd L'quilv insiruments are Llassifid aLLX)rdin8 u) the sllb￿nLe i)r ihe LiintraLLudl drrdn¥LmLnl.% LntLrl￿ iniii. An LNUiii insirumcnl is an). conlraci thai cvidcnces a residual inicrc5L in Lhe as%cl% or IhL Lh￿1() allLr dLduiiin¥ Jll ol'its liabililiL5. 2 Income from donat10115 and legacit5 Ilnrtslrir¢ed fund$ Restricted fund$ Total fund$ Donations rccciNablc 64? 871 ?28.236 871.107 Total for 2024 64? 871 2?8.23(1 871.107 Total for 2023 86.1.852 16().6.19 1.030.491 3 Income from other trading actiTr'itie5 Page li

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 UDresiri¢ted funds Restri¢ted funds runds TTading inLtsTtie- hop inL￿me 12.470 12.470 Total for 2024 12.47(1 Total for 2023 7.760 4 Inv¢sim¢ni In¢om¢ Llnrestrlcitd funds Totfil funds IntL'tht rLLI'iiable and similar inu)m¢: InterL$i rLccii'abl¢ on bank dep)sii$ 11.854 11.1154 Total for 2024 11.854 1.1454 Total for 2023 -.IY7 1..3Y7 S Exp¢ndltyr¢ on eharliiblt •¢ilvlll Ilnr¢stri¢¢¢d runds Total 2023 Rttlrieted 2024 Nole LurLiFKan QiinlLrcnce 2511.hX8 234.248 259.727 403.187 155.492 CifdnL% to in.%llLUllC)ns l.-uropLan Wcb%ile 234.248 9.582 9.582 25.841 22.077 Wiirk5hops l)LyrL'iiallVn. am()rii%Jiic)n and iiihir similar costs StatTc0515 G()i¢man¢e iwsti 2.551 109.782 5.347 2.551 1(19.78? 948 82.157 f).4h4 602.616 269.309 871.925 696.3h6 In addition to the eX￿ndituTe anali'sed aiK)i"e. Ihere are a150 gm"ernance r0515 of £5.347 12023 - £6.4041 which r¢laL¢ dir¢LtI) LO ¢h￿l￿bI¢ ￿liVIlI¢s. ntAe 6 rot futthtr d¢tsils. Page 16

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 6 Analysis of governance and sllPPOrt Costs GovernaDoe eosts Totol 2024 Totol 2023 IndcpLndLni c¥aminer lets ALL(iunLs indLpLnd¢nt examinkntion Payroll lix's Ilookeeping fees .1.900 87¥ 56() 5.400 4011 656 5..147 6.464 7 Net Inromlnglout%olng resourcts NL inu)min¥ rnSUUTLL8 1(w thL inLluik.'. 2024 2023 t)LprLiaii()n ol'li.¥ixl asscts 2.551 9411 8 Trustees remunerltlon And exptTrses l)uring the %'ear ¢he Lhariiy math ¢h& lolli)w"in8 tran&%tions ivith trusiee5'. Mr Ilarold C-.orrigin £61 h l?112_1.. £Nill c)I'L'x￿nSe% i*ere reimbur￿ L(Tr Mr Harold Corri8an durin8 ihe ￿ear. Ir Notl C'.orrig#n £205 12023.. £Nill c)I.LxFnS￿ were reimbursed 10 Mr Noel Corri8an durin8 ihe >ear. 9 Staff c05(s 'I'hr #g8rEgat¢ payroll costs w¢r¢ &$ follows: 21124 21123 Staff costs during the year were: Wag¢5 and 5Jlari¢s Social seLurity Costs Pension costs l(H.451 78.173 3.060 ?4 1.555 l(N.78? 82.157 No empli)!ee reLeived emoluments of more than £60,0￿ dllring the kear. Page 17

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 10 Tangible fixed assets Computer e4uiprnent Total c.ost .11 l FebruaTh' 2023 Additions l)isp(isu15 13.578 155 159¥1 13,578 155 15981 At 31 junu1￿ 2024 Deprtcixtion At l F'Lbruarn 2023 Lhar8e lor Ihe >ear l.'liminaied on disposals At 31 Januari 2(>24 6.963 2.551 6.IK>3 2,551 159NI 8.916 8.916 Net book vAlue At 31 Junuori 2024 At 31 JunuaTh 2023 4.219 4.21¥ 6.615 I I Stoek 2024 2023 Sloiks (Tr.635 7.38fi 12 Debto 2024 2023 Tradc dcbtor5 l¥cpa}'m¢nt5 other dehii)r 2.190 36.793 1.228 46.231 46.231 40.211 13 Cash and cash equivalents 2024 2023 C&5h (in h￿d Cash ai bank 25 1.142.047 383 970.663 1.142.072 971.046 Page 18

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 14 CreditOTS: amounts falling due within one year Z024 2023 Trade Lrtdili)r_% AccruJls tor 8ranis Uther taxation and social seeurilj ALLruu15 8.816 168.937 1.077 48,530 5.458 5.40(1 182.730 59.388 15 Obll2tlons und¢r l¢asts and hlrt pur¢has¢ ¢Olltra¢ts I'he loial I'alue ol. luiure minimum lease pa)'ments ii?s as tollom's.. 2024 2023 Within ()nL vL'ar In two 10 livL )ears 24.720 24.7211 16 C'ontlngent li#blllti¢s At 31 Janudr¥ 21124 bTrrJni% i)f £117.320 had been aM2rded fi)r wthiLh ￿ndl[lOnS r()r thc rcLx)8nilii)n in thL >Lar had not IK'Ln mct. 17 Funils Ctsrtertljefjr.. Bl•nc ¢ I Ftbrn#ry 202J Balance fit 31 J#nuorv 2024 Ineoming resources Rt50ur¢e5 expeDded Transfers Unre.Ytrl{'iedf￿Nrf.% (iLnLral Funds- all tund5 87fi.124 71M).5I7 I{￿18.887) 131.9231 935.831 Restricted Rc51riLlcd Rr5¢8r¢h Furtd5 European Websiie Projeci EuropLan Conference 2023 Extcrnal Projects 21.120 33,626 35.(XX) 21.120 23.606 110.0201 1191.8461 167.4431 124.923 103.313 31.923 TotAI re5tritted ¥9.746 22¥.236 126Y.3(191 31.923 V.596 Total fund$ 965.870 9?8.753 1878.1961 1.016.427 Page 19

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 PTIUT Jear.- Bal8nce •1 Febr￿ary 2022 Balance at 31 January 2023 llltomittg resources Resourtes expended Trnnsfe Unre5trlettd fllnds CiLnL'ral l.undb' . all lunds 502.965 873.IM)9 1475.7951 124.0551 876.124 Restricted RL%lTiiILJ Re%L¥rLh Fund% Eur()pLan W'ibsili ProjLx '.uropL'an C'onlerence 2022 .ur()pLun C-i)nlirLnLL 211Y3 21.120 42.828 59,74Y) 21.120 33.626 l6.6J9 115.(K)¢) 1?5.8411 1198.R451 24,055 Total restricted fund5 1•.1.7.3 12•4.()1161 24.1155 .74(1 Total fund$ 6?6.7{13 -1)34).6411 Y()5.11711 'I'h¥ %￿lItIL purw)%cq libr ￿h1¢h lh¢ fund% 10 bc appliLd are as follous: R¥%ifiLILd rL%iJrih fund% riprn'%imi th)naiion% 14'hL'r¢ lh¢ d(Trnor r¢4u¢si¢d ihat ih¢ir d(InaLlI)n h¢ u%¢d li)r rL%LafLh purpi.SLS lin1￿. -I'hL%L di)naiii)n% arL hLld ii'iihin rcsuiLILTrd fund% uniil USLXI in part l)T in whi)IL ti) lund a Lhi)lan8iCK4rnin(Ima re5earLh project which the charil>' commiited kn suprmriin8. Fti.%iriil¢d tunds l(Ir thi I..ur(l￿an li¢￿1¢¢ proj¢¢i r¢ry¢s¢ni dc)no¢ions i)r srA)n%)r4hips ￿"here th¢ di)ni)r l)as r¢qu¥%tL'd Ihdl Ihiir dc?ndti(In ￿. for this Pmj¥LI [￿1)..[.h¢￿L' th?ndti(Trn% Jr¥' hild within risiri¢t¥d fundb unlil U.%L,d in part i)r in ivhille ti) fund ihe LC)mple(ic)n i)fihe l..ur()pean ii'ehsiie pri)jeLi. Re5triclcd lunds for the European confcrtnce 2023 rtpre5eni donaiions or 5rKbn50r5hip5 ￿"here ¢he donor lias r¢qu¥%tid that thiir thinatii)n bi u.K.d fnr Ihis iT?nfirt'nix Iinl¥. 'lThis¢ (k?naiions 8r¢ held Mithin r¢siri¢t¥d funds uniil u%L'd in part i)r in ii'hi)le li) fund (he l-.uft)￿￿n LonferenLe ?073. Rc51riLILd lund5 fL)r the F.x(crnal Projclts rcprcscnl stKmsorship5 lo suptorL Indi￿IdUal. specific projccts AMMF ha5 undertakcn. "I"he numirr of projccts varl" l'ear from i"ear. 18 Analys15 of Det 855tts between fuDds Page 20

AMMF- The Cholangiocarcinoma Charity Notes to the Finalleial Statements for the Year Ended 31 January 2024 Total funds at 31 January Unrestricted fund5 Restricted funds 2024 TangiblL fixed assets Current &5seis C'urrent liubilitie5 4.219 1.114..?42 118? 7•91 4.219 1,194.938 1182.7291 8(I.596 .1 otal n¢t a￿lS 935.832 8U.596 .016.4?8 Total funds at JI January Ilnre51ricttd fund Rtstrirted futtds 2023 '] un8iblL fi¥ed &SSL C'urr¢nl &%5¢1% L urrL'ni liabililii 6.615 928.897 159..?881 6.615 1.01 8.643 159.38111 89.746 'I'uial nLI a*%L'¢S 117(1.124 8Y.74 19 Relfited pMr¢y trans¥¢tlons 'I'hL'rL %iLfL ni) rLIJiLd part! tran%a￿ion.S in the )'¢ar. Page21